TY - ABST

T1 - EP08.02-105 KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer

T2 - Characteristics and Outcomes from a Danish Nationwide Observational Study

AU - Frost, M.t.

AU - Gotfredsen, D.r.

AU - Petersen, T.s.

AU - Jensen, K.j.

AU - Solem, E.j.

AU - Sørensen, A.m.s.

AU - Louie, K.

AU - Sroczynski, N.

AU - Jakobsen, E.

AU - Andersen, J.l.

PY - 2022

Y1 - 2022

N2 - IntroductionTreatment targeting the KRAS p.G12C (G12C) mutation was approved by both the U.S. Food and Drug Administration and the European Medicines Agency in the past year as second line of treatment (LOT2) for advanced non-small-cell lung cancer (aNSCLC). However, the treatment-eligible G12C mutant NSCLC population has not been well characterized, nor has its outcomes with current treatment approaches. The aim of this study was to characterize a nationwide real-world G12C mutant NSCLC population and to estimate its overall survival (OS) in Denmark.Section snippetsMethodsAdult aNSCLC patients diagnosed between January 1st, 2018 and October 31st, 2020 were identified in the Danish Lung Cancer Register. The register has captured data on all Danish lung cancer patients since 2003. Additional information was gathered from the following registers: the Danish National Patient Register, the Danish Pathology Register, the Danish Civil Registration System, the Danish National Prescription Register, the Danish Education Register, and the Income Statistics Register.ResultsWe identified 6,058 patients with aNSCLC. A total of 36.5% (n=2,214) were tested with next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests for a KRAS mutation prior to LOT1. Among those tested, 40.5% (n=896) were KRAS mutated, 9.3% (n=206) were G12C mutated, and 39.0% (n=864) were KRAS/EGFR/ALK wild-type (Triple WT). Co-mutation with EGFR was present in 11% of G12C-mutated patients. Key characteristics and outcomes are presented in Table 1. TTNT was similar amongConclusionsThis Danish real-world study evaluating aNSCLC patients after the implementation of targeted therapy and immunotherapy showed that patients with a KRAS G12C mutation had a longer OS from LOT1 and LOT2 compared with Triple WT patients. The longer OS observed in patients with KRAS G12C mutant aNSCLC may be driven by higher PD-L1 expression and consequently more frequent use of immunotherapy.

AB - IntroductionTreatment targeting the KRAS p.G12C (G12C) mutation was approved by both the U.S. Food and Drug Administration and the European Medicines Agency in the past year as second line of treatment (LOT2) for advanced non-small-cell lung cancer (aNSCLC). However, the treatment-eligible G12C mutant NSCLC population has not been well characterized, nor has its outcomes with current treatment approaches. The aim of this study was to characterize a nationwide real-world G12C mutant NSCLC population and to estimate its overall survival (OS) in Denmark.Section snippetsMethodsAdult aNSCLC patients diagnosed between January 1st, 2018 and October 31st, 2020 were identified in the Danish Lung Cancer Register. The register has captured data on all Danish lung cancer patients since 2003. Additional information was gathered from the following registers: the Danish National Patient Register, the Danish Pathology Register, the Danish Civil Registration System, the Danish National Prescription Register, the Danish Education Register, and the Income Statistics Register.ResultsWe identified 6,058 patients with aNSCLC. A total of 36.5% (n=2,214) were tested with next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests for a KRAS mutation prior to LOT1. Among those tested, 40.5% (n=896) were KRAS mutated, 9.3% (n=206) were G12C mutated, and 39.0% (n=864) were KRAS/EGFR/ALK wild-type (Triple WT). Co-mutation with EGFR was present in 11% of G12C-mutated patients. Key characteristics and outcomes are presented in Table 1. TTNT was similar amongConclusionsThis Danish real-world study evaluating aNSCLC patients after the implementation of targeted therapy and immunotherapy showed that patients with a KRAS G12C mutation had a longer OS from LOT1 and LOT2 compared with Triple WT patients. The longer OS observed in patients with KRAS G12C mutant aNSCLC may be driven by higher PD-L1 expression and consequently more frequent use of immunotherapy.

U2 - 10.1016/j.jtho.2022.07.788

DO - 10.1016/j.jtho.2022.07.788

M3 - Conference abstract in journal

VL - 17

SP - S451

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 9

ER -